Gila Neta

Gila Neta

Auto-generated profile, based on publicly available information

Gila Neta

Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
LNLeticia M. Nogueira
Leticia M. Nogueira
TCTracy E. Crane
Tracy E. Crane
AOAna P. Ortiz
Ana P. Ortiz
HDHeather D'Angelo
Heather D'Angelo
GNGila Neta
Gila Neta
Climate change, the greatest threat to human health of our time, has implications for cancer control efforts throughout the cancer care continuum. The direct and indirect impacts of climate change on cancer risk, access to care, and outcomes are numerous and compounding, yet many oncology professionals might not be familiar with the strong connection between climate change and cancer. Thus, to increase awareness of this topic among cancer researchers, practitioners, and other professionals, this commentary discusses the links between climate change and cancer prevention and control, provides examples of adaptation and mitigation efforts, and describes opportunities and resources for future research.

10 November 2022 in The Lancet Planetary Health
Verified
Journal Article
Open access
GNGila Neta
Gila Neta
WPWilliam Pan
William Pan
KEKristie Ebi
Kristie Ebi
DBDaniel F Buss
Daniel F Buss
TCTrisha Castranio
Trisha Castranio
JBJohn Balbus
John Balbus
To date, there are few examples of implementation science studies that help guide climate-related health adaptation. Implementation science is the study of methods to promote the adoption and integration of evidence-based tools, interventions, and policies into practice to improve population health. These studies can provide the needed empirical evidence to prioritise and inform implementation of health adaptation efforts. This Personal View discusses five case studies that deployed disease early warning systems around the world. These cases studies illustrate challenges to deploying early warning systems and guide recommendations for implementation science approaches to enhance future research. We propose theory-informed approaches to understand multilevel barriers, design strategies to overcome those barriers, and analyse the ability of those strategies to advance the uptake and scale-up of climate-related health interventions. These findings build upon previous theoretical work by grounding implementation science recommendations and guidance in the context of real-world practice, as detailed in the case studies.

1 February 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
GNGila Neta
Gila Neta
MCMindy Clyne
Mindy Clyne
DCDavid A. Chambers
David A. Chambers
Background: To ensure investment in cancer research reaches populations who can benefit, the NCI has funded implementation science grants since the Dissemination and Implementation Research in Health (DIRH) funding opportunities launched in 2006. We analyzed NCI-funded DIRH grants to provide a snapshot of implementation science conducted across the cancer care continuum and highlight areas ripe for exploration. Methods: NCI-funded DIRH grants between fiscal years 2006 and 2019 were identified using the iSearch database. Two coders classified each grant by topic, populations studied, intervention and setting characteristics, strategies tested, study designs and methods used, and outcomes measured. Results: Seventy-one grants were awarded addressing cancer prevention (n = 33), screening (n = 33), diagnosis (n = 4), treatment (n = 9), and/or survivorship (n = 11). Colorectal (n = 20), breast (n = 15), and cervical (n = 11) were the most studied cancers. Most grants focused on delivery of guidelines (n = 36) or behavioral change interventions (n = 18) in health care settings (n = 47), studying implementation processes (n = 37) and/or testing implementation strategies (n = 43) using experimental (n = 35) and quasi-experimental (n = 6) designs. Few studied sustainability (n = 7), scale-up (n = 2), deimplementation (n = 4), measure development (n = 6), or policy-level implementation (n = 6). Conclusions: Current funding suggests researchers are studying implementation of cancer control interventions across the care continuum. However, research gaps remain in strategies for sustainability, scale-up, and deimplementation. More emphasis is needed on cancer treatment and survivorship. Additional focus on policy implementation and measure development is warranted. Impact: Understanding the breadth of NCI-funded implementation science can inform future efforts to build the knowledge base on how to improve dissemination and implementation of evidence in cancer control.

21 May 2018 in BMC Medicine
Verified
Journal Article
Open access
PDF file
GNGila Neta
Gila Neta
KJKarin E. Johnson
Karin E. Johnson
Real-world evidence is needed to inform real-world practice. Pragmatic controlled trials are intended to provide such evidence by assessing the effectiveness of medicines and other interventions in real-world settings, as opposed to explanatory trials that assess efficacy in highly controlled settings. Dal-Ré and colleagues (BMC Med 16:49, 2018) recently performed a literature review of studies published between 2014 and 2017 to assess the degree to which studies that self-identified as pragmatic were truly so. The authors found that over one-third of randomized controlled trials of drugs and biologics that were self-labeled as pragmatic used placebo controls (as opposed to usual care), tested medicines before licensing, or were conducted in a single site. Further, they proposed that, in order to improve the reliability of the ‘pragmatic’ label, investigators should assess their trials using the PRECIS-2 tool upon submission to funders, ethics boards, or journals. We appreciate the value of PRECIS-2 as an indicator to assess the pragmatic versus explanatory features in a trial, and we herein highlight the potential challenges and opportunities that may arise with its systematic and widespread use.

1 August 2022 in JCO Global Oncology
Verified
Journal Article
Open access
MPMark Parascandola
Mark Parascandola
GNGila Neta
Gila Neta
RSRamzi Salloum
Ramzi Salloum
DSDonna Shelley
Donna Shelley
ARAnne F. Rositch
Anne F. Rositch
PURPOSE: Although the global burden of cancer falls increasingly on low- and middle-income countries (LMICs), much of the evidence for cancer prevention and control comes from high-income countries and may not be directly applicable to LMIC settings. In this paper, we focus on the following question: When the majority of the evidence supporting an evidence-based intervention or implementation strategy comes from high-income countries, what local, contextual evidence is needed when transferring and adapting an intervention or strategy to a specific LMIC setting? METHODS: We draw on an existing framework (the Population, Intervention, Environment, Transfer-T process model) for assessing transferability of interventions between distinct settings and apply the model to two case studies as learning examples involving implementation of tobacco use treatment guidelines and self sampling for human papillomavirus DNA in cervical cancer screening. RESULTS: These two case studies illustrate how researchers, policymakers, practitioners, and consumers may approach the need for local evidence from different perspectives and with different priorities. As uses and expectations around local evidence may be different for different groups, aligning these priorities through multistakeholder engagement in which all parties participate in defining the questions and cocreating the solutions is critical, along with promoting standardized reporting of contextual factors. CONCLUSION: Local, contextual evidence can be important for both researchers and practitioners, and its absence may hinder translation of research and implementation efforts across different settings. However, it is essential for researchers, practitioners, and other stakeholders to be able to clearly articulate the type of data needed and why it is important. In particular, where resources are limited, evidence generation should be prioritized to address real needs and gaps in knowledge.

23 December 2022 in Environmental Health
Verified
Journal Article
Open access
PDF file
GNGila Neta
Gila Neta
LMLindsey Martin
Lindsey Martin
GCGwen Collman
Gwen Collman
Background: Environmental health sciences have identified and characterized a range of environmental exposures and their associated risk for disease, as well as informed the development of interventions, including recommendations, guidelines, and policies for mitigating exposure. However, these interventions only serve to mitigate exposures and prevent disease if they are effectively disseminated, adopted, implemented, and sustained. Main body: Numerous studies have documented the enormous time lag between research and practice, noting that dissemination and implementation are not passive processes but rely on active and intentional strategies. Implementation science seeks to build the knowledge base for understanding strategies to effectively disseminate and implement evidence and evidence-based interventions, and thus, bridge the research-to-practice gap. Conclusion: Environmental health researchers are well positioned to advance health promotion and disease prevention by incorporating implementation science into their work. This article describes the rationale for and key components of implementation science and articulates opportunities to build upon existing efforts to advance environmental health supported by the National Institute of Environmental Health Sciences and National Institutes of Health broadly.